Background: The potential impact of disease management to optimize quality of care, health
outcomes, and total healthcare costs across a range of cardiac disease states is unknown …

Aim To assess the long-term cost-effectiveness of an atrial fibrillation disease management
program (ie the SAFETY program) from the Australian healthcare system perspective …

Background Atrial fibrillation (AF) is a substantial burden on health care. Combined
specialist and nurse-based AF clinics are associated with improved outcomes. However …

Background The cost-effectiveness acceptability curve (CEAC) is a method for summarizing
the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint …

Atrial fibrillation (AF) is the most common heart rhythm arrhythmia, which has considerable
economic consequences. This study aims to identify the current cost-of-illness estimates of …

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Its prevalence is
estimated at 2.9% 1, 2, and it may be even higher if silent AF is considered 3, 4. 10 million …

Background: Atrial fibrillation (AF) is the most common sustained disorder of cardiac rhythm.
Various new anticoagulation and antiarrythmic treatments are being investigated for the …

Background Atrial fibrillation (AF) remains the most common form of cardiac arrhythmia.
Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via …

Objectives: Losses to follow‐up and administrative censoring can cloud the interpretation of
trial‐based economic evaluations. A number of investigators have examined the impact of …

Objectives Decision makers use models to assist in evaluating the cost-effectiveness of
pharmacologic stroke prevention in atrial fibrillation (SPAF). Study Design and Setting We …